The effect of Vancomycin and Gentamicin antibiotics on human osteoblast proliferation, metabolic function and bone mineralisation
Philp, Ashleigh M.; Saroop, Saeed; Newton Ede, Matthew P.; Jones, Simon

DOI: 10.1097/BRS.0000000000001712
License: None: All rights reserved

Document Version
Peer reviewed version

Citation for published version (Harvard):

Link to publication on Research at Birmingham portal

Publisher Rights Statement:
Eligibility for repository: Checked on 13/7/2016

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• Users may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 08. Aug. 2019
The effect of Vancomycin and Gentamicin antibiotics on human osteoblast proliferation, metabolic function and bone mineralisation

Ashleigh M Philp MSc¹, Saroop Raja¹, Andrew Philp PhD¹, Matthew P Newton Ede² MBBS †, Simon W Jones PhD¹†*

¹ MRC-ARUK Centre for Musculoskeletal Ageing Research, Institute of Inflammation and Ageing, Queen Elizabeth Hospital, University of Birmingham, B15 2WB.
² The Royal Orthopaedic Hospital NHS Foundation Trust, Bristol Road South, Northfield, Birmingham, B31 2AP.

* Corresponding author

Please address all correspondence to

Simon W Jones
MRC-ARUK Centre for Musculoskeletal Ageing Research,
Institute of Inflammation and Ageing,
Queen Elizabeth Hospital,
University of Birmingham,
B15 2WB
Email:s.w.jones@bham.ac.uk
+44 121 371 3224

† Denotes Joint Senior Authorship

This study was supported by the University of Birmingham

The manuscript does not contain information about medical devices or drugs
Structured Abstract

Study Design: This study investigates the effect of Vancomycin and Gentamicin antibiotics on primary human osteoblasts. Osteoblasts were incubated with vancomycin, gentamicin or with Povidone-Iodine (PVI), at concentrations advocated for wound irrigation. Osteoblast proliferation, metabolic function and bone mineralisation were measured.

Objective: To model Gentamicin and Vancomycin wound irrigation in vitro and examine the effect on osteoblast viability and cellular function in comparison to 0.35% PVI.

Summary of Background Data: Vancomycin, Gentamicin and dilute PVI are employed as wound irrigants in spinal surgery to reduce infection. However, we have recently demonstrated that 0.35% PVI has a detrimental effect on osteoblast cellular function and bone mineralisation. Studies to determine the effects of antibiotic wound irrigation solutions on osteoblasts and bone mineralisation are therefore warranted.

Methods: Primary human osteoblasts were exposed for 20 min to either PBS control, Vancomycin (35 mM or 3.5 mM), Gentamicin (34 mM or 3.4 mM) or 0.35% PVI for 3 min. Cellular proliferation was measured over 7 days by MTS assay. Osteoblast metabolic function was determined using a Seahorse XFe24 Bioanalyzer. Mineralised bone nodules were quantified using Alizarin red.
Vancomycin, Gentamicin and osteoblast proliferation

Results: At concentrations advocated for wound irrigation, both Gentamicin (3.4 mM) and Vancomycin (3.5 mM) induced a transient 15-20% reduction in osteoblast proliferation, which returned to control values within 72 h. This was in marked contrast to the effect of 0.35% PVI which resulted in a sustained reduction in osteoblast proliferation of between 40-50% over 7 days. Neither Gentamicin nor Vancomycin at concentrations up to 10x clinical dose had any effect on osteoblast oxygen consumption rate, or significantly affected mineralised bone nodule formation.

Conclusion: Vancomycin and Gentamicin solutions, at concentrations advocated for intrawound application in spinal surgery have a small but transient effect on osteoblast proliferation, and no effect on either osteoblast metabolic function or bone nodule mineralisation.

Key Words
Adolescent idiopathic scoliosis; osteoblasts; vancomycin; gentamicin; povidone iodine; PVI; bone; wound irrigation; antibiotics; bone mineralisation; cell proliferation, cell metabolism, surgical site infections

Level of Evidence: N/A
Key Points

- Acute exposure to clinically employed concentrations of Gentamicin and Vancomycin (3.4 mM and 3.5 mM respectively) induces a small but transient reduction in the proliferation of osteoblasts, in contrast to 0.35% PVI which induces a marked and sustained reduction in osteoblast proliferation.

- Gentamicin or Vancomycin up to 10x clinical dose did not affect osteoblast metabolic capacity (OCR), or effect bone nodule mineralisation, in contrast to 0.35% PVI.
Vancomycin, Gentamicin and osteoblast proliferation

Mini abstract

This study modelled the effect of using Gentamicin and Vancomycin antibiotics during spinal surgery on human primary osteoblast cells. Osteoblasts treated with clinically employed concentrations of Gentamicin or Vancomycin, exhibited a small but transient reduction in proliferation, and no change in metabolic capacity or ability to form mineralised bone.
**Introduction**

Surgical site infections (SSIs) following spinal surgery are a serious complication, which negatively impact on patient outcomes and can be fatal. Such incidences can require additional operations involving antibiotic irrigation of the wound and debridement, and in certain cases, the spinal implants must be removed: an expenditure of both time and healthcare resources. Indeed, infection-related costs have been reported to be an additional $30,000 per patient.

In order to combat infection, several prophylactic measures are in use. Peri-operative broad spectrum antibiotic usage is standard in orthopaedic surgery and does significantly reduce risk of infection. However, in addition, in order to reduce rates further, and due to the rise of Methicillin-Resistant *Staphylococcus Aureus* (MRSA), intrawound broad-spectrum antibiotics including Vancomycin and Gentamicin may be applied. Unfortunately, there are very few recommendations from historical literature with regards to the use of antibiotics to combat SSI rates in spinal surgery, and thus clinical practice varies considerably.

In a systematic review, particularly high SSI rates (3.5% to 8.5%) were noted in spinal surgery in paediatric patients with cerebral palsy, spina bifida, patients with urinary tract infections, incontinence obesity and those patients undergoing pelvic fixation procedures. This review was the basis for constructing the Best Practice Guidelines, where the intrawound application of Vancomycin is specifically recommended for spinal surgery in paediatric patients. Several studies, including large randomised control trials, have provided evidence that administration of intrawound Vancomycin is safe and efficacious in reducing the incidence of SSIs,
when compared to prophylactic antibiotics alone. Similarly, intrawound application of Gentamicin has also been shown to reduce infection rates spinal surgery in children with cerebral palsy, with a reduction from 15.2% to 3.9% observed.

Some spinal units have reported that wound irrigation with a solution of Povodine-Iodine (PVI; Betadine) is safe and efficacious at reducing SSI rates in spinal surgery. Furthermore, a protocol which combined PVI wound irrigation with intrawound Vancomycin powder was recently advocated as being highly effective at reducing SSI rates in spinal surgery, with a reduction of 50% reported. However, we have recently reported that exposure of human osteoblasts to 0.35% PVI (the concentration advocated for wound irrigation) is highly cytotoxic to osteoblasts, with a marked and sustained reduction in osteoblast cellular proliferation and inhibition of mineralised bone formation. This particular study highlighted the importance for spinal units to evaluate not only the SSI antibacterial efficacy of such intrawound reagents, but to also to consider the effect of these reagents on the cellular osteoblast function.

Critically, no studies have reported the effects of Vancomycin or Gentamicin antibiotics on human primary osteoblast mineralised bone formation. Neither has their effect on osteoblast proliferation been reported following an in vitro protocol that mimics the transient high concentrations of antibiotics in the surgical wound following intrawound application. Given that the goal of many spinal surgeries is to establish solid bone union, it is important to know whether these reagents, like PVI, may impair bone healing since this may help guide clinical practice. The aim of this study...
was therefore to model *in vitro* the effect of Vancomycin and Gentamicin antibiotic solutions on osteoblast proliferation, osteoblast metabolism and mineralised bone nodule formation.
METHODS

3.1 Cell culture

Ethical approval was granted by the United Kingdom (UK) National Research Ethics Service (National Health Authority, reference NRES 14-ES-1044), and institutionally approved and sponsored by the University of Birmingham as required under the UK Research Governance Framework. Study participants were provided in advance with a participant information sheet, and a participant consent form.

Following patient’s written consent, the femoral head was collected from a female patient (aged 62 years) undergoing total joint replacement surgery for hip osteoarthritis. The articular cartilage was removed from the femoral head and the subchondral bone cut into small chips. The bone chips were then washed thoroughly in serum-free primary osteoblast media to remove any excess blood, connective or adipose tissue and then incubated in differentiation media (10% FCS, penicillin (100units/ml), streptomycin (100µg/ml), L-glutamine (2mM), β-glycerophosphate (2mM), Ascorbic acid (50µg/ml) and Dexamethasone (10nM)) in a culture flask at 37°C (5% CO₂). Differentiation media was replaced with fresh media 2x per week, and the bone chips removed upon the appearance of osteoblast cells. Primary human osteoblast cells were cultured in differentiation media.

The experimental concentrations of Vancomycin and Gentamicin utilised for this study were based on the serial observation of average wound drain outputs following turning patients from the table. From this it was estimated that an average scoliosis wound held approximately 200 ml of fluid. Furthermore, it was considered that the majority of Vancomycin and Gentamicin antibiotic would be washed out after closure.
following opening of the drain after 20 min. Therefore an experimental concentration
of 1g of Vancomycin or Gentamicin in 200ml of PBS solution (equating to 3.5 mM
and 3.4 mM respectively) exposed for 20 min would best mimic the clinical
concentration and exposure time. Higher concentrations at 10X the estimated
clinical concentration was utilised for the second experimental setting, equating to 35
mM and 34 mM for Vancomycin and Gentamicin respectively. The experimental
concentration of PVI utilised was 0.35%, which has previously been clinically
advocated. Cells were exposed for 3 min with 0.35% PVI, before washing with PBS
in order to mimic the clinical saline washout procedure.

3.3 Osteoblast proliferation assay
Primary human osteoblasts were seeded at 6x10³ cells per well in a 96 well plate. At
confluency, osteoblasts were stimulated with either Vancomycin (3.5 mM or 35 mM),
or Gentamicin (3.4 mM or 34 mM) for 20 min, or with 0.35% PVI for 3 min. All wells
were then aspirated, washed 5x with PBS and then filled into osteoblast
differentiation media. After 0, 24, 48, 72 and 144 h incubation at 33°C, an MTS (Cell
Titer Aqueous One Solution Cell Proliferation Assay, Promega) assay was
performed as per manufacturer’s instructions as a measure of osteoblast
proliferation.

3.4 Osteoblast metabolic function
Primary human osteoblasts were plated at 6x10³ cells per well in a XF² 24 Cell
Culture Microplate (Seahorse Bioscience, USA). At confluency, the cells were
stimulated, washed and incubated exactly as in the proliferation assay and then
placed back into media. After 24 h incubation at 33°C, XF Assay medium (XF base medium with 2mM GlutaMAX™) was then added to the plate and incubated at 33°C for 1 h. Osteoblast oxygen consumption rate (OCR) was determined using a XF e Extracellular Flux Analyzer (Seahorse Bioscience, USA), as a measure of osteoblast metabolic function.

3.7 Osteoblast bone nodule formation and mineralization assay

Primary human osteoblasts were seeded at 6x10³ cells per well in an 96-well plate and stimulated, incubated and washed as previously described before being cultured in differentiation media. After 28 days, cells were stained with Alizarin red solution in order to quantify the degree of mineralisation following the formation of bone nodules. Briefly, cells were incubated in 0.5% Alizarin Red staining solution (Sigma-Aldrich, UK) in 1% ammonia solution at pH 4.5 for 10min at room temperature and washed with PBS to remove excess stain. Cells were then incubated in 10% cetylpyridinium chloride (Sigma-Aldrich, UK) for 10 min at room temperature. The supernatant was collected from each well and diluted 1:10 with the 10% cetylpyridinium chloride and read at OD₅₅₀nm on a SpectraMAX Microplate Reader (Molecular Devices, USA).

3.8 Statistical Analysis

All statistical analyses were carried out using SPSS. Unless otherwise stated, all data within figures represents Mean ±SEM and were assessed by a two-way analysis of variance (ANOVA) with a Bonferroni post-hoc test conducted where appropriate. Significance was accepted as P<0.05.
Vancomycin, Gentamicin and osteoblast proliferation

3.1 The effect of acute exposure to Vancomycin and Gentamicin antibiotics on osteoblast proliferative activity

Relative to normal osteoblast proliferation (PBS control), 20 min exposure of human osteoblasts to Gentamicin at the clinical concentration of 3.4 mM resulted in a significant reduction in osteoblast proliferation of 12% after 24h (P<0.05), and 22% after 48 h (P<0.01). However, at 3 days, osteoblast proliferation had returned to control levels. At 10x clinical dose of 34 mM Gentamicin, a similar reduction in osteoblast proliferation was observed, peaking at a 27% reduction after 48 h (P<0.001). However, osteoblasts exposed to 34 mM Gentamicin exhibited a more sustained reduction in osteoblast proliferation, with a significant 14% reduction (P<0.05) observed at 7 days post exposure (Figure 1A).

Vancomycin at 3.5 mM had no significant effect on osteoblast proliferation at 24 h, but there was a small 15% reduction in proliferation relative to control at 48 h. However, proliferation levels returned to control levels at 3 days post exposure. Similar to our findings with Gentamicin, the 10x clinical dose of 35 mM Vancomycin induced a more pronounced inhibition of osteoblast proliferation of between 18-24% and this effect was sustained up to 7 days post exposure (Figure 1B).

In contrast, osteoblasts exposed to 0.35% PVI for 3 min exhibited a much greater reduction in proliferation of between 40-50% which was sustained between 24 h and 7 days (P<0.001) (Figure 1A & 1B).
3.2 Acute exposure to Vancomycin and Gentamicin antibiotics does not affect human osteoblast basal metabolic function.

Given these differential findings between the effects of antibiotic reagents and PVI on osteoblast proliferation, we next compared their effects on osteoblast metabolic function. As we have previously reported, osteoblasts exposed for 3 min to 0.35% exhibit a significant 94% reduction (P<0.001) in basal oxygen consumption rate (OCR)\(^23\). However, in contrast neither Gentamicin nor Vancomycin, at either clinical dose or 10x clinical dose, elicited any significant reduction in osteoblast OCR. In osteoblasts that had been exposed 35 mM Vancomycin, OCR was on average lower than PBS control, although this did no reach statistical significance (Figure 2A & 2B).

3.4 Acute exposure of human osteoblasts to Vancomycin and Gentamicin does not inhibit the formation of mineralised bone

We next examined whether acute 20 min exposure of human osteoblasts to Vancomycin or Gentamicin had a chronic effect on their ability to form mineralised bone nodules. Following exposure to Vancomycin, Gentamicin or PBS control, confluent osteoblasts were kept in culture for a further 2 weeks before mineralised bone nodules were stained and quantified using Alizarin red (Figure 3A). Although, on average the degree of bone mineralisation was lower in osteoblasts which had been exposed to antibiotics, there was no significant reduction observed with either Gentamicin or Vancomycin at either clinical dose or 10x clinical dose (Figure 3B and 3C).
Discussion

This study shows that, at concentrations advocated for intrawound application, Vancomycin (3.5 mM) and Gentamicin (3.4 mM) elicit a small (15-20% reduction) in osteoblast proliferation. Critically however, this effect was transient, with osteoblast proliferation returning to normal within 72 h post-exposure. Furthermore, there was no impact on either osteoblast metabolic capacity or the ability of osteoblasts to form mineralised bone at these concentrations. These findings were in stark contrast to our findings with PVI, where the detrimental effects on osteoblast proliferation were significantly greater (40%-50% inhibition) and were sustained for up to 7 days.

These findings are clinically important since there are clear advantages to surgical intrawound application of antibiotics compared to intravenous administration. Firstly, in the Best Practice Guidelines, intrawound application of Vancomycin is favoured over intravenous delivery due to concerns about its potential systemic toxicity. Critically, although intrawound vancomycin is absorbed systemically, the systemic levels are low, thus higher concentrations can be applied where required without concerns for systemic toxicity. Furthermore, wounds are complicated by seroma, haematomas and devitalised tissue. Such tissues present barriers, which systemic prophylactic antibiotics poorly penetrate. Indeed, in a rabbit surgical wound infection model, intrawound Vancomycin was significantly more effective at eliminating SSIs than intravenous cefazolin alone.

Despite our data showing that Vancomycin (at 3.5 mM) and Gentamicin (at 3.4 mM) elicit only a small and transient effect on osteoblast proliferation, a previous study using the human MG-63 osteosarcoma cell line found that Vancomycin at 1000
Vancomycin, Gentamicin and osteoblast proliferation

100 ug/ml (equivalent to 0.68 mM) had no effect on cell viability, but was toxic at a
101 concentration of 10,000 ug/ml (6.8 mM). Similarly, Gentamicin at concentrations up
102 to 1000 ug/ml (2 mM) have previously been reported to reduce alkaline phosphatase
103 activity in osteoblast-like cells from cancellous hip bone. However, it is important
104 to note that firstly in the study by Edin et al. the utilised cells were not primary cells
105 and, although classed as “osteoblast-like”, their proliferation rate and alkaline
106 phosphatase activity is not considered very representative of bone. Secondly, in
107 the study by Edin et al. the cells were exposed to Vancomycin for 24-72 hours,
108 and in the study by Isefuku et al. cells were exposed to Gentamicin for 4 days.
109 Such lengthy in vitro protocols are likely to poorly mimic the transient high
110 concentration of Vancomycin within the surgical site following intrawound clinical
111 application. Our in vitro data supports clinical observations which report no
112 indications of bone growth problems in patients where bone allografts have been
113 supplemented with Vancomycin in hip revision surgery.

114 Importantly, despite the Best Practice Publication not including PVI irrigation
115 amongst the recommendations, the use of PVI either alone or in combination with
116 intrawound antibiotics is still being advocated by several spinal units. Furthermore, there are currently no clinical studies which have demonstrated greater
117 gains in reducing SSI rates using PVI irrigation compared to using intrawound
118 antibiotics. Therefore, given the clear differential effects we report here on
119 osteoblast viability, it would appear pertinent for clinicians to favour the practice of
120 intrawound Vancomycin or Gentamicin application over 0.35% PVI wound irrigation.
121 Furthermore, although the combination of Vancomycin intrawound with PVI wound
122 irrigation was recently reported to provide a commendable 50% reduction in SSI
Vancomycin, Gentamicin and osteoblast proliferation

rates in spinal surgery, our data suggests this practice should be approached cautiously. Such caution may be particularly warranted for paediatric patients undergoing long fusion surgical procedures (4 levels of more), with high non-union rates, where any gains in reducing SSI rates with PVI alone (or in combination with Vancomycin) may be offset by impaired bone healing.

It is important to stress the limitations of this study. It is an in vitro study, and although the human osteoblasts are primary cells they do not originate from spinal bone tissue. Furthermore, such in vitro studies cannot fully replicate the complexity of the in vivo environment, where for example pluripotent stem cells may migrate to the site of surgery and aid bone healing and fusion. Nevertheless, our data suggests a clear differential between the effects of Vancomycin and Gentamicin antibiotics compared to PVI on osteoblast proliferation and function.

In summary, at concentrations advocated for the reduction of SSIs in spinal surgery Vancomycin and Gentamicin had no sustained effect on osteoblast proliferation, or the formation of mineralised bone. We suggest therefore that in contrast to PVI wound irrigation, the intrawound application of the either Vancomycin or Gentamicin in spinal surgery would be unlikely to impair bone healing.
Vancomycin, Gentamicin and osteoblast proliferation

---

244 **Abbreviations**

245

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>PVI</td>
<td>Povidone-Iodine</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate buffered saline</td>
</tr>
<tr>
<td>MTS</td>
<td>3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt</td>
</tr>
</tbody>
</table>
References (cited in order of appearance)

Reference List


27. Isefuku S, Joyner CJ, Simpson AH. Gentamicin may have an adverse effect on osteogenesis. *J Orthop Trauma* 2003;17:212-6.


**Figure legends**

**Figure 1.** The effect of acute exposure to antibacterial intrawound reagents on primary human osteoblast proliferation. (A) Osteoblasts were stimulated for 20 min with either PBS control, Gentamicin (34 mM or 3.4 mM) or stimulated for 3 min with 0.35% PVI. (B) Osteoblasts were stimulated for 20 min with either PBS control, Vancomycin (35 mM or 3.5 mM) or stimulated for 3 min with 0.35% PVI. Osteoblast proliferation was measured by MTS assay (absorbance at 490 nm) at time 0, day 1, 3, 4 and day 7. Bars represent mean ± SEM (n=3), with *=P<0.05, †=P<0.01, ‡=P<0.001, representing values significantly different to PBS control.

**Figure 2.** Metabolic activity of primary human osteoblast following acute exposure to antibiotic intrawound reagents. (A) Oxygen consumption rate (OCR) of osteoblasts 24 h after 20 min exposure to either Gentamicin (34 mM or 3.4 mM) or 3 min exposure to 0.35% PVI. (B) OCR of osteoblasts after 20 min exposure to either Vancomycin (35 mM or 3.5 mM) or 3 min exposure to 0.35% PVI. Bars represent mean ± SEM (n=3), with ‡=P<0.001, representing values significantly different to PBS control.

**Figure 3.** Primary human osteoblast mineralisation following acute exposure to antibiotic intrawound reagents. (A) Representative microscopic images (x20 magnification) of phase contrast of primary human osteoblasts, and Alizarin red stained mineralised bony nodules after 28 days post fully confluent. Primary human osteoblasts were cultured out bone chips in differentiation media. (B) Quantification by absorptiometry (at 490 nm) of Alizarin red stained mineralised bone.
nODULES IN OSTEOSCLAST 14 DAYS AFTER ACUTE 20 MIN EXPOSURE TO EITHER GENTAMICIN (34 mM OR 3.4 mM), VANCOMYCIN (35 mM OR 3.5 mM) OR PBS MEDIA CONTROL. BARS REPRESENT MEAN ± SEM (n=3). (C) REPRESENTATIVE MICROSCOPIC IMAGES SHOWING IMAGES OF ALIZARIN RED STAINED MINERALISED BONE NODULES 14 DAYS AFTER EXPOSURE TO GENTAMICIN AND VANCOMYCIN ANTIBIOTICS.